China Food and Drug Administration Approves XeljanzChina, China Food and Drug Administration, FDA/Regulatory, Janus Kinase (JAK) Inhibitors, Rheumatoid ArthritisPfizer China announced that it has received approval from the CFDA to market its oral Janus kinase inhibitor, Xeljanz (tofacitinib citrate), in China for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Read more March 15, 2017/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2017-03-15 21:00:372017-03-16 03:09:18China Food and Drug Administration Approves Xeljanz
